<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36525477</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>129</EndPage><MedlinePgn>118-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51708</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To compare serum levels of the astrocyte biomarker glial fibrillary acidic protein (GFAP) in patients with amyotrophic lateral sclerosis (ALS) and neurologically healthy controls and to analyze the relations between serum GFAP (sGFAP) and phenotype in ALS.</AbstractText><AbstractText Label="METHODS">We studied 114 ALS patients and 38 controls. sGFAP was quantified with single molecule array (Simoa) technology.</AbstractText><AbstractText Label="RESULTS">In both ALS patients and controls, sGFAP moderately correlated with age. ALS patients had higher sGFAP levels compared to controls, but this yielded a weak discriminative performance (AUC&#xa0;=&#xa0;0.6198). In ALS, sGFAP was not associated with most of the motor phenotypic features, including site of onset, functional status, disease progression rate, disease stage, and indices of upper (UMN) and lower motor neuron (LMN) impairment. However, sGFAP negatively correlated with cognitive scores regarding ALS-nonspecific functions, particularly memory (r&#xa0;=&#xa0;-0.2082) and tended to be higher in ALS patients with eye movement abnormalities (p&#xa0;=&#xa0;0.0628). sGFAP also correlated with polysomnographic indices of oxygen desaturation (ODI; r&#xa0;=&#xa0;0.2639) and apnea-hypopnea (AHI; r&#xa0;=&#xa0;0.2858). In a multivariate analysis, sGFAP was negatively associated with survival (HR&#xa0;=&#xa0;1.005). Relevantly, we found a negative correlation between sGFAP and estimated glomerular filtration rate (eGFR; r&#xa0;=&#xa0;-0.3500).</AbstractText><AbstractText Label="INTERPRETATION">Our work provides neurochemical evidence of astrocyte involvement in ALS pathophysiology and particularly in the development of extra-motor manifestations (namely, cognitive - memory - impairment) and respiratory dysfunction. The negative correlation between sGFAP and eGFR has practical relevance and should not be disregarded in future investigations.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3977-6995</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milone</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maranzano</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solca</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doretti</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Residency Program, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manini</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Residency Program, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetti</LastName><ForeName>Ruggero</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Residency Program, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peverelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maderna</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratti</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7698-3854</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5963-7426</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>16</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36525477</ArticleId><ArticleId IdType="pmc">PMC9852391</ArticleId><ArticleId IdType="doi">10.1002/acn3.51708</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et&#xa0;al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084&#x2010;2098. doi:10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al&#x2010;Chalabi A, et&#xa0;al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):465&#x2010;479. doi:10.1016/S1474-4422(21)00414-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, et&#xa0;al. The frontotemporal dementia&#x2010;motor neuron disease continuum. Lancet. 2016;388(10047):919&#x2010;931. doi:10.1016/S0140-6736(16)00737-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Silani V, Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32(5):747&#x2010;757. doi:10.1097/WCO.0000000000000744</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000744</ArticleId><ArticleId IdType="pubmed">31403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Otto M, Silani V. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199. doi:10.3389/fnins.2021.679199</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.679199</ArticleId><ArticleId IdType="pmc">PMC8255624</ArticleId><ArticleId IdType="pubmed">34234641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7&#x2010;35. doi:10.1007/s00401-009-0619-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0619-8</ArticleId><ArticleId IdType="pmc">PMC2799634</ArticleId><ArticleId IdType="pubmed">20012068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D, Kato T, Kushner PD. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res. 1994;38(3):336&#x2010;347. doi:10.1002/jnr.490380312</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490380312</ArticleId><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci. 1996;139:27&#x2010;33. doi:10.1016/0022-510x(96)00073-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(96)00073-1</ArticleId><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet&#x2010;Phillips AM, Hester ME, Miranda CJ, et&#xa0;al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(9):824&#x2010;828. doi:10.1038/nbt.1957</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421&#x2010;443. doi:10.1016/j.pneurobio.2011.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.01.005</ArticleId><ArticleId IdType="pubmed">21219963</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhak A, Foschi M, Abu&#x2010;Rumeileh S, et&#xa0;al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158&#x2010;172. doi:10.1038/s41582-021-00616-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00616-3</ArticleId><ArticleId IdType="pubmed">35115728</ArticleId></ArticleIdList></Reference><Reference><Citation>Korley FK, Jain S, Sun X, et&#xa0;al. Prognostic value of day&#x2010;of&#x2010;injury plasma GFAP and UCH&#x2010;L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK&#x2010;TBI cohort: an observational cohort study. Lancet Neurol. 2022;21(9):803&#x2010;813. doi:10.1016/S1474-4422(22)00256-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00256-3</ArticleId><ArticleId IdType="pmc">PMC9462598</ArticleId><ArticleId IdType="pubmed">35963263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Janelidze S, Smith R, et&#xa0;al. Plasma GFAP is an early marker of amyloid&#x2010;beta but not tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505&#x2010;3516. doi:10.1093/brain/awab223</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab223</ArticleId><ArticleId IdType="pmc">PMC8677538</ArticleId><ArticleId IdType="pubmed">34259835</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninger F, Glat MJ, Offen D, Steiner I. Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Clin Neurosci. 2016;26:75&#x2010;78. doi:10.1016/j.jocn.2015.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2015.10.008</ArticleId><ArticleId IdType="pubmed">26602604</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, et&#xa0;al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90(1):4&#x2010;10. doi:10.1136/jnnp-2018-318868</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone YM, Domi T, Mandelli A, et&#xa0;al. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol. 2022;29(7):1930&#x2010;1939. doi:10.1111/ene.15321</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15321</ArticleId><ArticleId IdType="pmc">PMC9314044</ArticleId><ArticleId IdType="pubmed">35263489</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2010;299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS Study Group . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2010;746. doi:10.1136/jnnp.2010.235952</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et&#xa0;al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1&#x2013;2):13&#x2010;21. doi:10.1016/s0022-510x(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et&#xa0;al. Progression rate of ALSFRS&#x2010;R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2010;267. doi:10.1212/01.wnl.0000194316.91908.8a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain&#x2010;Barre syndrome. Muscle Nerve. 1991;14(11):1103&#x2010;1109. doi:10.1002/mus.880141111</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880141111</ArticleId><ArticleId IdType="pubmed">1745285</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Edmundson C, Dahodwala N, Elman L. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve. 2020;61(4):508&#x2010;511. doi:10.1002/mus.26764</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26764</ArticleId><ArticleId IdType="pubmed">31743477</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine MS, Ballard E, O'Rourke P, Kiernan MC, McCombe PA, Henderson RD. Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3&#x2013;4):184&#x2010;190. doi:10.3109/21678421.2015.1125502</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1125502</ArticleId><ArticleId IdType="pubmed">26700804</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranzano A, Poletti B, Solca F, et&#xa0;al. Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2022;29(5):1402&#x2010;1409. doi:10.1111/ene.15243</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15243</ArticleId><ArticleId IdType="pubmed">34989063</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas&#x2010;Garcia R, Scott KM, et&#xa0;al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(Pt 3):847&#x2010;852. doi:10.1093/brain/awr351</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38&#x2010;44. doi:10.1136/jnnp-2013-306589</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L, et&#xa0;al. Association of clinically evident eye movement abnormalities with motor and cognitive features in patients with motor neuron disorders. Neurology. 2021;97(18):e1835&#x2010;e1846. doi:10.1212/WNL.0000000000012774</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012774</ArticleId><ArticleId IdType="pubmed">34504031</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L, et&#xa0;al. The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7&#x2013;8):489&#x2010;498. doi:10.1080/21678421.2016.1183679</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1183679</ArticleId><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et&#xa0;al. Amyotrophic lateral sclerosis &#x2013; frontotemporal spectrum disorder (ALS&#x2010;FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3&#x2013;4):153&#x2010;174. doi:10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et&#xa0;al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456&#x2010;2477. doi:10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti S, Bonazzi S, Laiacona M, Masina M, Coralli MV. Montreal cognitive assessment (MoCA) &#x2013; Italian version:&#xa0;regression based norms and equivalent scores. Neurol Sci. 2015;36(2):209&#x2010;214. doi:10.1007/s10072-014-1921-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-014-1921-3</ArticleId><ArticleId IdType="pubmed">25139107</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621&#x2010;1626. doi:10.1212/wnl.55.11.1621</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.55.11.1621</ArticleId><ArticleId IdType="pubmed">11113214</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberici A, Geroldi C, Cotelli M, et&#xa0;al. The frontal behavioural inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease. Neurol Sci. 2007;28(2):80&#x2010;86. doi:10.1007/s10072-007-0791-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-007-0791-3</ArticleId><ArticleId IdType="pubmed">17464470</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561&#x2010;571. doi:10.1001/archpsyc.1961.01710120031004</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1961.01710120031004</ArticleId><ArticleId IdType="pubmed">13688369</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano M, Trojano L, Trojsi F, Monsurro MR, Tedeschi G, Santangelo G. Assessing anxiety and its correlates in amyotrophic lateral sclerosis: the state&#x2010;trait anxiety inventory. Muscle Nerve. 2019;60(1):47&#x2010;55. doi:10.1002/mus.26475</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26475</ArticleId><ArticleId IdType="pubmed">30897219</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel M, Glatz C, Helmle C, Young P, Drager B, Boentert M. Respiratory parameters on diagnostic sleep studies predict survival in patients with amyotrophic lateral sclerosis. J Neurol. 2021;268(11):4321&#x2010;4331. doi:10.1007/s00415-021-10563-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10563-0</ArticleId><ArticleId IdType="pmc">PMC8505303</ArticleId><ArticleId IdType="pubmed">33880611</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et&#xa0;al. A new equation&#xa0;to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604&#x2010;612. doi:10.7326/0003-4819-150-9-200905050-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto M, Bowser R, Turner M, et&#xa0;al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012;13(1):1&#x2010;10. doi:10.3109/17482968.2011.627589</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.627589</ArticleId><ArticleId IdType="pubmed">22214350</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Mila&#x2010;Aloma M, Vrillon A, et&#xa0;al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471&#x2010;1483. doi:10.1001/jamaneurol.2021.3671</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3671</ArticleId><ArticleId IdType="pmc">PMC8524356</ArticleId><ArticleId IdType="pubmed">34661615</ArticleId></ArticleIdList></Reference><Reference><Citation>Silani V, Pizzuti A, Redaelli LM, et&#xa0;al. ALS cerebrospinal fluid enhances human foetal astroglial cell proliferation in&#xa0;vitro. Adv Exp Med Biol. 1987;209:79&#x2010;81. doi:10.1007/978-1-4684-5302-7_13</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4684-5302-7_13</ArticleId><ArticleId IdType="pubmed">3577935</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J, Huang C, Bi F, et&#xa0;al. Expression of ALS&#x2010;linked TDP&#x2010;43 mutant in astrocytes causes non&#x2010;cell&#x2010;autonomous motor neuron death in rats. EMBO J. 2013;32(13):1917&#x2010;1926. doi:10.1038/emboj.2013.122</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.122</ArticleId><ArticleId IdType="pmc">PMC3981181</ArticleId><ArticleId IdType="pubmed">23714777</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, Brambilla L, Valori CF, et&#xa0;al. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 2008;15(11):1691&#x2010;1700. doi:10.1038/cdd.2008.99</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2008.99</ArticleId><ArticleId IdType="pubmed">18617894</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmachari S, Fung YK, Pahan K. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci. 2006;26(18):4930&#x2010;4939. doi:10.1523/JNEUROSCI.5480-05.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5480-05.2006</ArticleId><ArticleId IdType="pmc">PMC1963412</ArticleId><ArticleId IdType="pubmed">16672668</ArticleId></ArticleIdList></Reference><Reference><Citation>Burtrum D, Silverstein FS. Hypoxic&#x2010;ischemic brain injury stimulates glial fibrillary acidic protein mRNA and protein expression in neonatal rats. Exp Neurol. 1994;126(1):112&#x2010;118. doi:10.1006/exnr.1994.1047</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1994.1047</ArticleId><ArticleId IdType="pubmed">8157121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>